Jingwen Yao

Assistant Professor, Radiological Sciences, University of California Los Angeles

UC Profile

Dr. Jingwen Yao is an Assistant Professor in the Department of Radiological Sciences at UCLA and a faculty member of the Physics & Biology in Medicine graduate program. She earned her M.B.B.S. in China and completed her Ph.D. in Bioengineering at UCLA, followed by postdoctoral training at UCSF. Dr. Yao's research is centered on developing advanced MRI techniques for applications in brain tumors and other neurological diseases. She is particularly interested in developing and validating MRI biomarkers that reflect physiological and pathological tissue properties for disease progression monitoring and treatment effect assessment. Dr. Yao’s current research includes (1) developing and validating imaging biomarkers sensitive to the brain tumor microenvironment, such as tissue acidity, immune infiltration, and tumor vasculature, (2) developing and applying advanced imaging for pathophysiological characterization and treatment targeting in movement disorders. Her research encompasses various aspects of biomarker development, including sequence development, image acquisition and reconstruction, post-processing, quantitative image analysis, and clinical translation and evaluation.

Interests

Deep Brain Stimulation, Brain Tumor, Chemical Exchange Saturation Transfer, Huntington's Disease, Neuroimaging, Quantitative Susceptibility Mapping, Magnetic Resonance Imaging

Education and Training

University of California, San FranciscoPostdoc12/2022Radiology and Biomedical Imaging
University of California, Los AngelesPh.D.03/2021Bioengineering
University of California, Los AngelesM.S.05/2017Chemistry and Biochemistry
Shanghai Jiao Tong UniversityM.B.B.S.07/2015Clinical Medicine

Awards and Honors

  • UC Chancellor's Postdoctoral Fellowship, University of California, 2022.

Publications

  1. Yao J, Morrison MA, Jakary A, Avadiappan S, Chen Y, Luitjens J, Glueck J, Driscoll T, Geschwind MD, Nelson AB, Villanueva-Meyer JE, Hess CP, Lupo JM. Comparison of quantitative susceptibility mapping methods for iron-sensitive susceptibility imaging at 7T: An evaluation in healthy subjects and patients with Huntington's disease.. NeuroImage, 2022.
  2. Cho NS, Hagiwara A, Yao J, Nathanson DA, Prins RM, Wang C, Raymond C, Desousa BR, Divakaruni A, Morrow DH, Nghiemphu PL, Lai A, Liau LM, Everson RG, Salamon N, Pope WB, Cloughesy TF, Ellingson BM. Amine-weighted chemical exchange saturation transfer magnetic resonance imaging in brain tumors.. NMR in biomedicine, 2022.
  3. Hagiwara A, Oughourlian TC, Cho NS, Schlossman J, Wang C, Yao J, Raymond C, Everson R, Patel K, Mareninov S, Rodriguez FJ, Salamon N, Pope WB, Nghiemphu PL, Liau LM, Prins RM, Cloughesy TF, Ellingson BM. Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.. Neuro-oncology, 2022.
  4. Yao J, Hagiwara A, Oughourlian TC, Wang C, Raymond C, Pope WB, Salamon N, Lai A, Ji M, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM. Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study.. Cancers, 2022.
  5. Goldman J, Hagiwara A, Yao J, Raymond C, Ong C, Bakhti R, Kwon E, Farhat M, Torres C, Erickson LG, Curl BJ, Lee M, Pope WB, Salamon N, Nghiemphu PL, Ji M, Eldred BS, Liau LM, Lai A, Cloughesy TF, Chung C, Ellingson BM. Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease.. Frontiers in oncology, 2022.
  6. Hagiwara A, Tatekawa H, Yao J, Raymond C, Everson R, Patel K, Mareninov S, Yong WH, Salamon N, Pope WB, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM. Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI.. Scientific reports, 2022.
  7. Hagiwara A, Yao J, Raymond C, Cho NS, Everson R, Patel K, Morrow DH, Desousa BR, Mareninov S, Chun S, Nathanson DA, Yong WH, Andrei G, Divakaruni AS, Salamon N, Pope WB, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM. "Aerobic glycolytic imaging" of human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imaging.. NeuroImage. Clinical, 2021.
  8. Akbari H, Kazerooni AF, Ware JB, Mamourian E, Anderson H, Guiry S, Sako C, Raymond C, Yao J, Brem S, O'Rourke DM, Desai AS, Bagley SJ, Ellingson BM, Davatzikos C, Nabavizadeh A. Quantification of tumor microenvironment acidity in glioblastoma using principal component analysis of dynamic susceptibility contrast enhanced MR imaging.. Scientific reports, 2021.
  9. Bydder M, Ali F, Saucedo A, Hagiwara A, Wang C, Pham AD, Yao J, Ellingson BM. A study of 3D radial density adapted trajectories for sodium imaging.. Magnetic resonance imaging, 2021.
  10. Tatekawa H, Uetani H, Hagiwara A, Yao J, Oughourlian TC, Ueda I, Raymond C, Lai A, Cloughesy TF, Nghiemphu PL, Liau LM, Bahri S, Pope WB, Salamon N, Ellingson BM. Preferential tumor localization in relation to 18F-FDOPA uptake for lower-grade gliomas.. Journal of neuro-oncology, 2021.
  11. Wang C, Holly LT, Oughourlian T, Yao J, Raymond C, Salamon N, Ellingson BM. Detection of cerebral reorganization associated with degenerative cervical myelopathy using diffusion spectral imaging (DSI).. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2021.
  12. Yao J, Wang C, Raymond C, Bergstrom B, Chen X, Das K, Dinh H, Kim ZS, Le AN, Lim MWJ, Pham JAN, Prusan JD, Rao SS, Nathanson DA, Ellingson BM. A physical phantom for amine chemical exchange saturation transfer (CEST) MRI.. Magma (New York, N.Y.), 2021.
  13. Bydder M, Ali F, Ghodrati V, Hu P, Yao J, Ellingson BM. Minimizing echo and repetition times in magnetic resonance imaging using a double half-echo k-space acquisition and low-rank reconstruction.. NMR in biomedicine, 2020.
  14. Oughourlian TC, Yao J, Hagiwara A, Nathanson DA, Raymond C, Pope WB, Salamon N, Lai A, Ji M, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM. Relative oxygen extraction fraction (rOEF) MR imaging reveals higher hypoxia in human epidermal growth factor receptor (EGFR) amplified compared with non-amplified gliomas.. Neuroradiology, 2020.
  15. Patel KS, Everson RG, Yao J, Raymond C, Goldman J, Schlossman J, Tsung J, Tan C, Pope WB, Ji MS, Nguyen NT, Lai A, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM. Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.. Neurosurgery, 2020.
  16. Yao J, Wang C, Ellingson BM. Influence of phosphate concentration on amine, amide, and hydroxyl CEST contrast.. Magnetic resonance in medicine, 2020.
  17. Tatekawa H, Hagiwara A, Uetani H, Yao J, Oughourlian TC, Bahri S, Wang C, Raymond C, Lai A, Cloughesy TF, Nghiemphu PL, Liau LM, Pope WB, Salamon N, Ellingson BM. Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas.. Journal of neuro-oncology, 2020.
  18. Patel KS, Yao J, Raymond C, Yong W, Everson R, Liau LM, Nathanson D, Kornblum H, Wang C, Oughourlian T, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM. Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma.. Scientific reports, 2020.
  19. Yao J, Hagiwara A, Raymond C, Shabani S, Pope WB, Salamon N, Lai A, Ji M, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM. Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study.. Scientific reports, 2020.
  20. Tatekawa H, Hagiwara A, Yao J, Oughourlian TC, Ueda I, Uetani H, Raymond C, Lai A, Cloughesy TF, Nghiemphu PL, Liau LM, Pope WB, Salamon N, Ellingson BM. Voxelwise and Patientwise Correlation of 18F-FDOPA PET, Relative Cerebral Blood Volume, and Apparent Diffusion Coefficient in Treatment-Naïve Diffuse Gliomas with Different Molecular Subtypes.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020.
  21. Ellingson BM, Yao J, Raymond C, Nathanson DA, Chakhoyan A, Simpson J, Garner JS, Olivero AG, Mueller LU, Rodon J, Gerstner E, Cloughesy TF, Wen PY. Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2020.
  22. Oughourlian TC, Yao J, Schlossman J, Raymond C, Ji M, Tatekawa H, Salamon N, Pope WB, Czernin J, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM. Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas.. Journal of neuro-oncology, 2020.
  23. Yao J, Chakhoyan A, Nathanson DA, Yong WH, Salamon N, Raymond C, Mareninov S, Lai A, Nghiemphu PL, Prins RM, Pope WB, Everson RG, Liau LM, Cloughesy TF, Ellingson BM. Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI.. Neuro-oncology, 2019.
  24. Chakhoyan A, Raymond C, Chen J, Goldman J, Yao J, Kaprealian TB, Pouratian N, Ellingson BM. Probabilistic independent component analysis of dynamic susceptibility contrast perfusion MRI in metastatic brain tumors.. Cancer imaging : the official publication of the International Cancer Imaging Society, 2019.
  25. Chakhoyan A, Yao J, Leu K, Pope WB, Salamon N, Yong W, Lai A, Nghiemphu PL, Everson RG, Prins RM, Liau LM, Nathanson DA, Cloughesy TF, Ellingson BM. Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry.. Scientific reports, 2019.
  26. Yao J, Tan CHP, Schlossman J, Chakhoyan A, Raymond C, Pope WB, Salamon N, Lai A, Ji M, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM. pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma.. Journal of neuro-oncology, 2019.
  27. Ellingson BM, Yao J, Raymond C, Chakhoyan A, Khatibi K, Salamon N, Villablanca JP, Wanner I, Real CR, Laiwalla A, McArthur DL, Monti MM, Hovda DA, Vespa PM. pH-weighted molecular MRI in human traumatic brain injury (TBI) using amine proton chemical exchange saturation transfer echoplanar imaging (CEST EPI).. NeuroImage. Clinical, 2019.
  28. Yao J, Ruan D, Raymond C, Liau LM, Salamon N, Pope WB, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM. Improving B0 Correction for pH-Weighted Amine Proton Chemical Exchange Saturation Transfer (CEST) Imaging by Use of k-Means Clustering and Lorentzian Estimation.. Tomography (Ann Arbor, Mich.), 2018.
  29. Patel CB, Fazzari E, Chakhoyan A, Yao J, Raymond C, Nguyen H, Manoukian J, Nguyen N, Pope W, Cloughesy TF, Nghiemphu PL, Czernin J, Lai A, Ellingson BM. 18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study.. Journal of neuro-oncology, 2018.
  30. Harris RJ, Yao J, Chakhoyan A, Raymond C, Leu K, Liau LM, Nghiemphu PL, Lai A, Salamon N, Pope WB, Cloughesy TF, Ellingson BM. Simultaneous pH-sensitive and oxygen-sensitive MRI of human gliomas at 3 T using multi-echo amine proton chemical exchange saturation transfer spin-and-gradient echo echo-planar imaging (CEST-SAGE-EPI).. Magnetic resonance in medicine, 2018.
  31. Yao J, Hsu CH, Li Z, Kim TS, Hwang LP, Lin YC, Lin YY. Magnetic Resonance Nano-Theranostics for Glioblastoma Multiforme.. Current pharmaceutical design, 2015.